A phase I pharmacokinetic and pharmacodynamic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group Study

Trial Profile

A phase I pharmacokinetic and pharmacodynamic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group Study

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2013

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top